AI Article Synopsis

  • In-hospital mortality rates for patients experiencing cardiogenic shock remain high, even with advanced support devices like VA-ECMO and Impella.
  • A study analyzed blood samples from 11 patients before and after device implantation, focusing on changes in the plasma proteome using SOMAscan technology.
  • The findings indicated that both ECMO and Impella lead to reduced inflammatory markers and increased cell death among inflammatory cells, suggesting that these proteins could be potential targets for new treatments or biomarkers in managing acute myocardial circulatory support (AMCS).

Similar Publications

Background: Immune checkpoint inhibitors (ICIs) are effective antineoplastic agents but can cause adverse effects in many organ systems. Cardiovascular toxicities include arrhythmias, myocarditis, heart failure, takotsubo syndrome, pericarditis, coronary artery disease, and vasculitis.

Case Summary: A 66-year-old woman with Stage 3C2 endometrial carcinoma presented for her second cycle of pembrolizumab, carboplatin, and paclitaxel.

View Article and Find Full Text PDF

Validity and Accuracy of the Derived Left Ventricular End-Diastolic Pressure in Impella 5.5.

Circ Heart Fail

January 2025

Department of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Germany. (R.P., J.S.H., D.B., A.S.M., M.H., A.Z., G.D., J.D.S., A.F.P., A.W., A.R., B.S.).

Background: Consensus regarding on-support evaluation and weaning concepts from Impella 5.5 support is scarce. The derived left ventricular end-diastolic pressure (dLVEDP), estimated by device algorithms, is a rarely reported tool for monitoring the weaning process.

View Article and Find Full Text PDF

Background: There is a lack of data on the role of chronic kidney disease (CKD) in patients who received percutaneous left ventricular assist devices (pLVAD) as mechanical circulatory support (MCS) as an adjunct treatment for cardiogenic shock (CS) management.

Methods: Using National Inpatient Sample (2016-19), we extracted CS patients receiving pLVAD and divided them into CKD and non-CKD cohorts. Multivariate regression analysis was used for adjusted odds ratios for outcomes before and after entropy balancing (EB) and predictive margins for the probability of all-cause in-hospital mortality (ACM).

View Article and Find Full Text PDF

Background: Impella 5.5 ventricular assist device (VAD) insertion is typically done via the axillary artery or directly through the aorta; however, an axillary artery must be ≥6 mm in diameter, which excludes many pediatric patients who do not meet this criterion. The innominate artery is a larger vessel that can better accommodate the Impella VAD in pediatric patients.

View Article and Find Full Text PDF

Objectives: The benefit of combining multiple mechanical circulatory support (MCS) systems in patients with cardiogenic shock (CS) is debated. This review examines patient characteristics across studies to identify differences and assesses if patients with a higher-risk clinical profile receive Impella unloading.

Design: A systematic review and meta-analysis was conducted to examine if there were significant differences in baseline clinical parameters among patients receiving MCS in addition to venoarterial extracorporeal membrane oxygenation (VA ECMO).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!